News Vertex Pharmaceuticals Incorporated

Stocks

VRTX

US92532F1003

Pharmaceuticals

Market Closed - Nasdaq 21:00:00 16/10/2026 BST			5-day change	1st Jan Change
499.74 ^USD	-1.77%		-2.03%	+10.23%

10-15	Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $654 From $653	MT
10-09	Vertex Pharmaceuticals Says Alyftrek Delivers Pancreatic Function Recovery in Some Children	MT

All News

Mentions Relevance

10-15	Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $654 From $653	MT
10-09	Vertex Pharmaceuticals Says Alyftrek Delivers Pancreatic Function Recovery in Some Children	MT
10-09	Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference	BU
10-09	Vertex Pharmaceuticals Incorporated Presents New Interim Data on Alyftrek in Children Ages 2 to 5 Years At the North American Cystic Fibrosis Conference	CI
10-08	RBC Lifts Price Target on Vertex Pharmaceuticals to $576 From $570, Keeps Outperform Rating	MT
10-07	Vertex to Announce Third Quarter 2026 Financial Results November 2nd	BU
10-07	Vertex Pharmaceuticals Incorporated Presents at Bank of America Global Healthcare Conference 2026, Sep-23-2026 09:05 AM
09-28	UBS Raises Vertex Pharmaceuticals Price Target to $615 From $585, Maintains Buy Rating	MT
09-23	TD Cowen Adjusts PT on Vertex Pharmaceuticals to $550 From $525, Maintains Buy Rating	MT
09-23	Jefferies Adjusts Price Target on Vertex Pharmaceuticals to $640 From $633, Maintains Buy Rating	MT
09-22	Vertex Pharmaceuticals Incorporated Announces Positive Results From Phase 2b AMPLIFIED Study Of Inaxaplin And Completes Enrollment In The Phase 2/3 AMPLITUDE Trial	CI
09-22	Vertex Pharmaceuticals Reports Positive Results for Inaxaplin Kidney Disease Trial	MT
09-22	Vertex Announces Positive Results From Phase 2b AMPLIFIED Study of Inaxaplin in Additional Populations of People With APOL1-Mediated Kidney Disease (AMKD) and Completion of Enrollment in the Phase 2/3 AMPLITUDE Trial	BU
09-15	Vertex Partners With World Champion Skier Lindsey Vonn to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe Acute Pain	BU
09-14	Vertex Pharmaceuticals Incorporated Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-14-2026 07:00 AM
09-10	Vertex Pharmaceuticals Incorporated Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference, Sep-10-2026 02:10 PM
09-10	Vertex Pharmaceuticals Incorporated Presents at Wells Fargo 21st Annual Healthcare Conference, Sep-09-2026 04:30 PM
09-02	Evercore ISI Adjusts Vertex Pharmaceuticals Price Target to $600 From $535, Maintains Outperform Rating	MT
09-01	Vertex Pharmaceuticals Incorporated Announces Chief Financial Officer Changes, Effective January 1, 2027	CI
09-01	Vertex Pharmaceuticals Incorporated Appoints Jonathan Poole as Executive Vice President, Effective January 1, 2027	CI
09-01	Vertex Names Jonathan Poole Finance Chief as Crinetics Buy Closes	DJ
09-01	Vertex Pharmaceuticals Closes Crinetics Pharmaceuticals Acquisition	MT
09-01	Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team	BU
08-26	Vertex to Participate in Upcoming September Investor Conferences	BU
08-12	Vertex Has Multiple Portfolio Catalysts With Favorable Risk-Reward, RBC Says	MT